ACP Diabetes Monthly
Welcome to this month's issue of ACP Diabetes Monthly, an update for internists published by the American College of Physicians.
In the News for the month of February 2017
Position statement on diabetic neuropathy urges early recognition, appropriate management
The American Diabetes Association offered advice on prevention, screening, and treatment of diabetic peripheral neuropathies and cardiovascular autonomic neuropathies. More...
Sickle cell trait affects HbA1c's accuracy as a measure of glycemia, study finds
Mean HbA1c was 5.7% in the African-American participants with sickle cell trait and 6.0% in those without, despite similar mean fasting and two-hour glucose values. More...
Continuous glucose monitoring associated with lower HbA1c in type 1 diabetes treated with insulin injection
An editorial accompanying the two trials of continuous glucose monitoring stressed that the physicians involved had extensive experience with the technology and noted that the necessary changes in lifestyle and insulin dosing can be variable and complicated. More...
MKSAP quiz: Insulin pump management
This month's quiz asks readers to evaluate a 43-year-old man with multiple chronic complications from his diabetes, including end-stage kidney disease requiring hemodialysis, gastroparesis, frequent hypoglycemia with hypoglycemic unawareness, painful peripheral neuropathy, and proliferative retinopathy. More...
Spotlight on HIV and diabetes
Multiple recent studies focused on HIV and diabetes, looking at incidence of diabetes among patients with HIV, the effectiveness of medications in patients with both conditions, and efforts to improve nutrition in patients with one or both conditions. More...
From ACP Journal Club
Review: In type 2 diabetes, sodium–glucose cotransporter 2 inhibitors do not increase major CV events or mortality
The meta-analysis included 37 trials that compared canagliflozin, dapagliflozin, or empagliflozin to placebo or other active antidiabetic treatments. More...
Semaglutide reduced a composite of CV events at two years in patients with type 2 diabetes and high CV risk
Semaglutide, a new once-weekly glucagon-like peptide-1 (GLP-1) analogue, reduced cardiovascular (CV) events compared to placebo, according to a manufacturer-sponsored study. More...
From ACP Internist Weekly
Exercise tips for type 1 diabetes offered by consensus statement
The consensus statement advises physicians about ways to manage people with type 1 diabetes who exercise regularly, including glucose targets for safe and effective exercise and nutritional and insulin dose adjustments to protect against exercise-related glucose excursions. More...
Physician editor: David V. O'Dell, MD, FACP
About ACP Diabetes Monthly
ACP Diabetes Monthly is a monthly newsletter produced by the staff of ACP Internist. It is automatically sent to all College members who have an email address on file with ACP.
To sign up for ACP Diabetes Monthly, please click here.
Copyright © by American College of Physicians.
A 67-year-old man is evaluated for a recent diagnosis of primary hyperparathyroidism after an elevated serum calcium level was incidentally detected on laboratory testing. Medical history is significant only for hypertension, and his only medication is ramipril. Following a physical exam and lab studies, what is the most appropriate management of this patient?
Not an ACP Member?
Join today and discover the benefits waiting for you.
ACP offers different categories of membership depending on your career stage and professional status. View options, pricing and benefits.
A New Way to Ace the Boards!
Ensure you're board-exam ready with ACP's Board Prep Ace - a multifaceted, self-study program that prepares you to pass the ABIM Certification Exam in internal medicine. Learn more.